0132 The effect of zoledronic acid in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole: 24 months integrated follow-up of the Z-FAST/ZO-FAST trials
Antonio Frassoldati(Italian Oncology Group of Clinical Research), RE Coleman(Weston Park Cancer Centre), Natasha Schenk(Novartis (United States)), Outi Paija(Turku University Hospital), Peyman Hadji(Philipps University of Marburg), N.J. Bundred(University of Manchester), R. Lambert-Falls, Raul Mena, Adam Brufsky(University of Pittsburgh)
Cited by 5
Related Papers
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
|Annals of Oncology|2012|339